Combined hydroxypropyl-β-cyclodextrin and poly(anhydride) nanoparticles improve the oral permeability of paclitaxel

European Journal of Pharmaceutical Sciences

Volumn 38, Issue 4, 2009, Pages 405-413

  Agueros M ^a   Ruiz Gaton L ^a   Vauthier, C ^b   Bouchemal, K ^b   Espuelas, S ^a   Ponchel, G ^b   Irache, J M ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Bioadhesion; Cyclodextrin; Intestinal permeability; Nanoparticles; Paclitaxel; Poly(anhydride); Ussing chambers

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; NANOPARTICLE; PACLITAXEL; POLY(ANHYDRIDE); UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG PENETRATION; DRUG RELEASE; DRUG SOLUBILITY; INTESTINE EPITHELIUM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 70349840419     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2009.09.010     Document Type: Article

References (43)

1. Agüeros M., Areses P., Campanero M.A., Salman H.H., Quincoces G., Peñuelas I., and Irache J.M. Bioadhesive properties and biodistribution of cyclodextrin-poly(anhydride) nanoparticles. Eur. J. Pharm. Sci. 37 (2009) 231-240
2. Arbos P., Arangoa M.A., Campanero M.A., and Irache J.M. Quantification of the bioadhesive properties of protein-coated PVM/MA nanoparticles. Int. J. Pharm. 242 (2002) 129-136
3. Arbos P., Campanero M.A., Arangoa M.A., and Irache J.M. Nanoparticles with specific bioadhesive properties to circumvent the pre-systemic degradation of fluorinated pyrimidines. J. Control. Release 96 (2004) 55-65
4. Arbos P., Campanero M.A., Arangoa M.A., Renedo M.J., and Irache J.M. Influence of the surface characteristics of PVM/MA nanoparticles on their bioadhesive properties. J. Control. Release 89 (2003) 19-30
5. Arima H., Yunomae K., Hirayama F., and Uekama K. Contribution of P-glycoprotein to the enhancing effects of dimethyl-beta-cyclodextrin on oral bioavailability of tacrolimus. J. Pharmacol. Exp. Ther. 297 (2001) 547-555
6. Bravo-Osuna I., Vauthier C., Chacun H., and Ponchel G. Specific permeability modulation of intestinal paracellular pathway by chitosan-poly(isobutyl cyanoacrylate) core-shell nanoparticles. Eur. J. Pharm. Biopharm. 69 (2008) 436-444
7. Cai Q.X., Zhu K.J., Chen D., and Gao L.P. Synthesis, characterization and in vitro release of 5-aminosalicylic acid and 5-acetyl aminosalicylic acid of polyanhydride-P(CBFAS). Eur. J. Pharm. Biopharm. 55 (2003) 203-208
8. Dong Y., and Feng S.S. Poly(d,l-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs. Biomaterials 26 (2005) 6068-6076
9. Duchene D., and Ponchel G. Combined poly(alkykcyanoacrilate)/cyclodextrin nanoparticles. J. Inclus. Phen. Macrocyclic. Chem. 44 (2004) 15-16
10. Fenyvesi F., Fenyvesi E., Szente L., Goda K., Bacso Z., Bacskay I., Varadi J., Kiss T., Molnar E., Janaky T., Szabo Jr. G., and Vecsernyes M. P-glycoprotein inhibition by membrane cholesterol modulation. Eur. J. Pharm. Sci. 34 (2008) 236-242
11. Gao P., Rush B.D., Pfund W.P., Huang T., Bauer J.M., Morozowich W., Kuo M.S., and Hageman M.J. Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability. J. Pharm. Sci. 92 (2003) 2386-2398
12. Grau J.J., Caballero M., Verger E., Monzo M., and Blanch J.L. Weekly paclitaxel for platin-resistant stage IV head and neck cancer patients. Acta Otolaryngol. (2008) 1-6
13. Green H., Soderkvist P., Rosenberg P., Mirghani R.A., Rymark P., Lundqvist E.A., and Peterson C. Pharmacogenetic studies of paclitaxel in the treatment of ovarian cancer. Basic Clin. Pharmacol. Toxicol. 104 (2009) 130-137
14. Higuchi T., and Connors K.A. Phase-solubility techniques. Adv. Anal. Chem. Instrum. 4 (1965) 117-212
15. Ishikawa M., Yoshii H., and Furuta T. Interaction of modified cyclodextrins with cytochrome P-450. Biosci. Biotechnol. Biochem. 69 (2005) 246-248
16. Khandavilli S., and Panchagnula R. Nanoemulsions as versatile formulations for paclitaxel delivery: peroral and dermal delivery studies in rats. J. Invest. Dermatol. 127 (2007) 154-162
17. Kintzel P.E. Prophylaxis for paclitaxel hypersensitivity reactions. Ann. Pharmacother. 35 (2001) 1114-1117
18. Kruijtzer C.M., Beijnen J.H., and Schellens J.H. Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview. Oncologist 7 (2002) 516-530
19. Lambert G., Fattal E., Pinto-Alphandary H., Gulik A., and Couvreur P. Polyisobutylcyanoacrylate nanocapsules containing an aqueous core as a novel colloidal carrier for the delivery of oligonucleotides. Pharm. Res. 17 (2000) 707-714
20. Letchford K., Liggins R., Wasan K.M., and Burt H. In vitro human plasma distribution of nanoparticulate paclitaxel is dependent on the physicochemical properties of poly(ethylene glycol)-block-poly(caprolactone) nanoparticles. Eur. J. Pharm. Biopharm. 71 (2009) 196-206
21. Lionetto M.G., Giordano M.E., De Nuccio F., Nicolardi G., Hoffmann E.K., and Schettino T. Hypotonicity induced K+ and anion conductive pathways activation in eel intestinal epithelium. J. Exp. Biol. 208 (2005) 749-760
22. Loftsson T., Hreinsdottir D., and Masson M. Evaluation of cyclodextrin solubilization of drugs. Int. J. Pharm. 302 (2005) 18-28
23. Malingre M.M., Beijnen J.H., and Schellens J.H. Oral delivery of taxanes. Invest. New Drugs 19 (2001) 155-162
24. Mardones P., Andrinolo D., Csendes A., and Lagos N. Permeability of human jejunal segments to gonyautoxins measured by the Ussing chamber technique. Toxicon 44 (2004) 521-528
25. Monza da Silveira A., Ponchel G., Puisieux F., and Duchene D. Combined poly(isobutylcyanoacrylate) and cyclodextrins nanoparticles for enhancing the encapsulation of lipophilic drugs. Pharm. Res. 15 (1998) 1051-1055
26. Nornoo A.O., Zheng H., Lopes L.B., Johnson-Restrepo B., Kannan K., and Reed R. Oral microemulsions of paclitaxel: in situ and pharmacokinetic studies. Eur. J. Pharm. Biopharm. 71 (2009) 310-317
27. Overmoyer B. Options for the treatment of patients with taxane-refractory metastatic breast cancer. Clin. Breast Cancer 8 Suppl. 2 (2008) S61-70
28. Peltier S., Oger J.M., Lagarce F., Couet W., and Benoit J.P. Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules. Pharm. Res. 23 (2006) 1243-1250
29. Rowinsky E.K., and Donehower R.C. Paclitaxel (taxol). N. Engl. J. Med. 332 (1995) 1004-1014
30. Roy V., LaPlant B.R., Gross G.G., Bane C.L., and Palmieri F.M. Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531). Ann. Oncol. 20 (2009) 449-453
31. Salman H.H., Gamazo C., Campanero M.A., and Irache J.M. Salmonella-like bioadhesive nanoparticles. J. Control. Release 106 (2005) 1-13
32. Salman H.H., Gamazo C., Campanero M.A., and Irache J.M. Bioadhesive mannosylated nanoparticles for oral drug delivery. J. Nanosci. Nanotechnol. 6 (2006) 3203-3209
33. Schittenhelm M.M., Kollmannsberger C., Oechsle K., Harlow A., Morich J., Honecker F., Kurek R., Storkel S., Kanz L., Corless C.L., Wong K.K., Bokemeyer C., and Heinrich M.C. Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer. Mol. Cancer Ther. 8 (2009) 481-489
34. Singla A.K., Garg A., and Aggarwal D. Paclitaxel and its formulations. Int. J. Pharm. 235 (2002) 179-192
35. Sparreboom A., van Asperen J., Mayer U., Schinkel A.H., Smit J.W., Meijer D.K., Borst P., Nooijen W.J., Beijnen J.H., and van Tellingen O. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 2031-2035
36. Varma M.V., and Panchagnula R. Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo. Eur. J. Pharm. Sci. 25 (2005) 445-453
37. Wadell C., Bjork E., and Camber O. Nasal drug delivery-evaluation of an in vitro model using porcine nasal mucosa. Eur. J. Pharm. Sci. 7 (1999) 197-206
38. Walle T. Assays of CYP2C8- and CYP3A4-mediated metabolism of taxol in vivo and in vitro. Methods Enzymol. 272 (1996) 145-151
39. Weiss R.B., Donehower R.C., Wiernik P.H., Ohnuma T., Gralla R.J., Trump D.L., Baker Jr. J.R., Van Echo D.A., Von Hoff D.D., and Leyland-Jones B. Hypersensitivity reactions from taxol. J. Clin. Oncol. 8 (1990) 1263-1268
40. Woo J.S., Lee C.H., Shim C.K., and Hwang S.J. Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031. Pharm. Res. 20 (2003) 24-30
41. Yang S., Gursoy R.N., Lambert G., and Benita S. Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors. Pharm. Res. 21 (2004) 261-270
42. Yoncheva K., Gomez S., Campanero M.A., Gamazo C., and Irache J.M. Bioadhesive properties of pegylated nanoparticles. Expert. Opin. Drug. Deliv. 2 (2005) 205-218
43. Zhang Z., and Feng S.S. Self-assembled nanoparticles of poly(lactide)-Vitamin E TPGS copolymers for oral chemotherapy. Int. J. Pharm. 324 (2006) 191-198